• Company
• Opdivo approved as 1st-line Tx for urothelial cell carcinoma
• by Hwang, Byung-woo Jul 23, 2024 05:48am

• Company
• "Trodelvy gives new hope for triple-negative breast cancer"
• by Son, Hyung-Min Jul 23, 2024 05:48am

• Company
• Eisai reports degrowth for 3 consecutive years
• by Hwang, Byung-woo Jul 23, 2024 05:47am

• Company
• Atopic dermatitis drugs get expanded indication for infants
• by Eo, Yun-Ho Jul 23, 2024 05:47am

• Company
• Hyperlipidemia Drug Leqvio’s nears market entry in KOR
• by Hwang, Byung-woo Jul 23, 2024 05:47am

• Company
• Efforts to develop a new drug for dry eye syndrome continue
• by Son, Hyung-Min Jul 22, 2024 05:51am

• Company
• The 1st cardiomyopathy drug 'Camzyos' lands in hospitals
• by Eo, Yun-Ho Jul 22, 2024 05:50am

• Company
• 'Prostate cancer market leader' Astellas eyes on KRW 300 bil
• by Hwang, Byung-woo Jul 19, 2024 05:48am

• Company
• 'Adtralza' lands in general hospitals in KOR
• by Eo, Yun-Ho Jul 19, 2024 05:47am

• Company
• Forxiga generics, Jardiance·Envlo, surpass original drug
• by Kim, Jin-Gu Jul 18, 2024 05:49am